RE: An outstanding RNS19 Mar 2021 07:35
From today's RNS
"The two companies have signed a five year contract (US$8m in the first two years, at which point the contract is subject to renewal) which is expected to deliver US$30m of royalty revenue to the Company.."
HEIQ's 1 HY2020 revenue was US$30m
and from the Jan 2021 trading update
"The Company expects to report that revenue for FY 2020 exceeded market expectations. This was due to a robust performance delivered by HeiQ's core portfolio of products, including a particularly strong sales performance from its antimicrobial technology, HeiQ Viroblock, which was launched during the Period. Since then, it has been applied to over 1 billion facemasks and won the Swiss Technology Award in Q4 2020."